Publication
The Clinical Development of Percutaneous Heart Valve Technology: A Position Statement of the Society of Thoracic Surgeons (STS), the American Association for Thoracic Surgery (AATS), and the Society for Cardiovascular Angiography and Interventions (SCAI)
Thomas A. Vassiliades, Jr, Peter C. Block, Lawrence H. Cohn, David H. Adams, Jeffrey S. Borer, Ted Feldman, David R. Holmes, Warren K. Laskey, Bruce W. Lytle, Michael J. Mack and David O. Williams
This joint position statement represents the combined efforts of four professional societies (Society of Thoracic Surgeons [STS], American Association for Thoracic Surgery [AATS], American College of Cardiology [ACC], and Society for Cardiovascular Angiography and Interventions [SCAI]), two government agencies (the U.S. Food and Drug Administration [FDA] and the Centers for Medicare and Medicaid Services [CMS]), and numerous industry representatives to assess the foreseeable directions of a class of emerging technologies being developed to enable the percutaneous treatment of cardiac valve dysfunction.
Page Created: Jan. 04, 2018
Last Updated: Jan. 04, 2018
Share
Publications
-
Developing a mitral valve center of excellence
Ahmed El-Eshmawi, MD, Javier G. Castillo, MD, David H. Adams, MD -
Prosthesis Type for Aortic- and Mitral-Valve Replacement
Joanna Chikwe, MD, Eugene H. Blackstone, MD, David H. Adams, MD -
Bioprosthetic aortic valve replacement: revisiting prosthesis choice in patients younger than 50 years old
Samuel R. Schnittman, MD, David H. Adams, MD, Shinobu Itagaki, MD, Nana Toyoda, MD, Natalia N. Egorova, PhD, Joanna Chikwe, MD -
Real world outcomes of surgery for native mitral valve endocarditis
Samuel R. Schnittman, MD, David H. Adams, MD, Shinobu Itagaki, MD, Nana Toyoda, MD, Natalia N. Egorova, PhD, Joanna Chikwe, MD